Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial

AIMS: Sacubitril/valsartan improves morbidity and mortality in patients with heart failure and reduced ejection fraction (HFrEF). Whether initiation of sacubitril/valsartan limits the use and dosing of other elements of guideline‐directed medical therapy for HFrEF is unknown. We examined the effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhatt, Ankeet S., Vaduganathan, Muthiah, Claggett, Brian L., Liu, Jiankang, Packer, Milton, Desai, Akshay S., Lefkowitz, Martin P., Rouleau, Jean L., Shi, Victor C., Zile, Michael R., Swedberg, Karl, Vardeny, Orly, McMurray, John J.V., Solomon, Scott D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2021
Materias:
Dug Titration and Adherence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291580/
https://www.ncbi.nlm.nih.gov/pubmed/34101308
http://dx.doi.org/10.1002/ejhf.2259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291580/
https://www.ncbi.nlm.nih.gov/pubmed/34101308
http://dx.doi.org/10.1002/ejhf.2259

Ejemplares similares